We've already got commitments from 42 investment firms from 8 countries to attend BioTrinity 2010, including a number of corporate venture funds including the recently launched OSI Investment Holdings and a growing number of investment banks. Last year, where we attracted nearly 40 investment firms by the time of the conference in April, so we are well on course to achieve our target of 100 delegates from 60-70 investment firms, among some 650 delegates.
Key: VC, Corporate Venturer, Investment Bank, Angel
Abingworth Management
Advent Venture Partners
Albion Ventures LLP
Andy Richards (serial entrepreneur)
Atlas Venture
Beringea
Canaccord Adams
Edmond de Rothschild Investment Partners (France)
Entrepreneurs Fund
Esperante Ventures (Netherlands)
ETV Capital
Excalibur Group (formerly Merlin Biosciences)
Forbion Capital Partners (Netherlands)
Genzyme Ventures
H2O Venture Partners
IP Group plc
Ipso Ventures
IQ Capital
Mercia Technology Seed Fund
MVM Life Science Partners
New Hill Management
NESTA
NGN Capital
Nomura Code Securities
Novo Ventures (Denmark)
Orion Healthcare Equity Partners (USA)
Oxford Capital Partners
Oxford Technology Management
Piper Jaffray
Rainbow Seed Fund
Rosetta Capital
Seraphim Capital
Seroba Kernel (Ireland)
Seventure
Sofinnova Ventures (France)
SPARK Ventures
SR One (USA)
Takeda Research Investment Inc (USA)
The Wellcome Trust